Hypha Labs, INC. (FUNI) — SEC Filings

Q: What are the key financial highlights for Hypha Labs, INC.?

Key financial highlights for Hypha Labs, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Hypha Labs, INC.?

Key executives at Hypha Labs, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Hypha Labs, INC. stock?

Risk factors for Hypha Labs, INC. (FUNI) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Hypha Labs, INC.?

Forward-looking statements and predictions from Hypha Labs, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Hypha Labs, INC.. Recent 10-Q filing on Aug 21, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Hypha Labs, INC. on SEC EDGAR

Overview

Hypha Labs, INC. (FUNI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Aug 21, 2025: Hypha Labs, Inc. (FUNI) reported no revenue for the three and nine months ended June 30, 2025, a significant shift from its previous cannabis testing business. The company's net loss from continuing operations widened to $2,543,486 for the nine months ended June 30, 2025, compared to a net loss of $

Sentiment Summary

Across 15 filings, the sentiment breakdown is: 2 bearish, 13 neutral. The dominant filing sentiment for Hypha Labs, INC. is neutral.

Filing Type Overview

Hypha Labs, INC. (FUNI) has filed 6 10-Q, 6 8-K, 2 10-K, 1 10-K/A with the SEC between Jan 2024 to Aug 2025.

Filings by Year

2025 · 2024

Recent Filings (15)

Hypha Labs Shifts to Mushroom Tech, Reports Zero Revenue Amid Rising Losses — 10-Q · Aug 21, 2025 Risk: high
Hypha Labs, Inc. (FUNI) reported no revenue for the three and nine months ended June 30, 2025, a significant shift from its previous cannabis testing business.
Hypha Labs Narrows Q2 Loss to $1K Amidst Stable Capital Structure — 10-Q · Jun 13, 2025 Risk: high
Hypha Labs, Inc. (FUNI) reported a net loss of $1,000 for the three months ended March 31, 2025, a significant improvement from the $1,000 net loss reported for
Hypha Labs (fka Digipath) Files Q1 2025 10-Q — 10-Q · Feb 14, 2025 Risk: low
Hypha Labs, Inc. filed its 10-Q for the period ending December 31, 2024. The company, formerly known as Digipath, Inc., is incorporated in Nevada and operates i
Hypha Labs Reports Material Agreements & Officer Changes — 8-K · Jan 24, 2025 Risk: medium
Hypha Labs, Inc. (formerly Digipath, Inc.) filed an 8-K on January 24, 2025, reporting several key events as of January 21, 2025. These include entering into a
Hypha Labs, Inc. Files 8-K for Bylaws and Financials — 8-K · Jan 16, 2025 Risk: low
Hypha Labs, Inc. (formerly Digipath, Inc.) filed an 8-K on January 16, 2025, reporting changes related to its Articles of Incorporation or Bylaws and financial
Hypha Labs, Inc. Files 2024 10-K — 10-K · Jan 13, 2025 Risk: medium
Hypha Labs, Inc. filed its 10-K for the fiscal year ending September 30, 2024, reporting on its operations as a testing laboratory. The company, formerly known
Hypha Labs Files 8-K: Material Agreement, Equity Sales — 8-K · Dec 16, 2024 Risk: medium
Hypha Labs, Inc. (formerly Digipath, Inc.) entered into a material definitive agreement on December 10, 2024. The company also reported on unregistered sales of
Hypha Labs (fka Digipath) Files Q3 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
Hypha Labs, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Digipath, Inc., is incorporated in Nevada and operates in te
Hypha Labs, Inc. Files 10-Q for Q2 2024 — 10-Q · May 20, 2024 Risk: medium
Hypha Labs, Inc. filed its 10-Q for the period ending March 31, 2024. The company, formerly known as Digipath, Inc., is incorporated in Nevada and operates in t
Hypha Labs Files 8-K for Bylaw Amendments and Financials — 8-K · Apr 15, 2024 Risk: low
Hypha Labs, Inc. filed an 8-K on April 15, 2024, reporting events that occurred on March 12, 2024. The filing indicates amendments to its Articles of Incorporat
Digipath Announces Board Changes and Compensation Adjustments — 8-K · Mar 1, 2024 Risk: medium
Digipath, Inc. announced on February 29, 2024, a change in its board of directors and executive compensation arrangements. The filing details the departure of c
Digipath Completes Asset Acquisition/Disposition — 8-K · Feb 23, 2024 Risk: medium
Digipath, Inc. filed an 8-K on February 23, 2024, reporting the completion of an acquisition or disposition of assets on February 20, 2024. The filing indicates
Digipath, Inc. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 14, 2024 Risk: low
Digipath, Inc. (FUNI) filed a Quarterly Report (10-Q) with the SEC on February 14, 2024. Digipath, Inc. filed a 10-Q report for the period ending December 31, 2
Digipath, Inc. Files 10-K/A Amendment for Fiscal Year Ended September 30, 2023 — 10-K/A · Jan 19, 2024 Risk: low
Digipath, Inc. (FUNI) filed a Amended Annual Report (10-K/A) with the SEC on January 19, 2024. Digipath, Inc. filed an amended 10-K for the fiscal year ending S
Digipath, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Jan 16, 2024 Risk: low
Digipath, Inc. (FUNI) filed a Annual Report (10-K) with the SEC on January 16, 2024. Digipath, Inc. filed its 10-K report for the fiscal year ending September 3

Risk Profile

Risk Assessment: Of FUNI's 15 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Hypha Labs, INC.'s most recent 10-Q filing (Aug 21, 2025):

Revenue: $0
Net Income: N/A
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $147,192
Operating Margin: N/A
Total Assets: N/A
Total Debt: $2,186,704

Industry Context

The home appliance market for food production is an emerging sector. Hypha Labs is attempting to carve out a niche with its Hypha Micropearl accelerator for mushroom cultivation. This market is characterized by innovation and a growing consumer interest in home-grown food, but also faces challenges in consumer education and adoption of new technologies.

Top Tags

10-Q (5) · quarterly-report (3) · Digipath (3) · Testing Laboratories (2) · material-agreement (2) · corporate-governance (2) · financial-reporting (2) · 10-K (2) · testing-laboratories (2) · Biotechnology (1)

Key Numbers

Revenue: $0 — No revenue for the three and nine months ended June 30, 2025, indicating a complete operational shift.
Net Loss from Continuing Operations: $(2,543,486) — Increased from $(904,586) in 2024, reflecting higher operating expenses.
General and Administrative Expenses: $1,172,261 — Increased from $683,456 for the nine months ended June 30, 2024, contributing to wider losses.
Professional Fees: $1,338,192 — Significantly increased from $574,728 for the nine months ended June 30, 2024, indicating higher legal/consulting costs.
Cash: $147,192 — As of June 30, 2025, a slight increase from $91,166 on September 30, 2024, primarily from financing activities.
Total Current Liabilities: $2,186,704 — Increased from $1,393,660 on September 30, 2024, driven by notes payable and accounts payable.
Accumulated Deficit: $23,090,912 — Widened from $20,547,426 on September 30, 2024, reflecting ongoing losses.
Common Shares Outstanding: 145,121,825 — As of August 21, 2025, an increase from 123,046,825 on September 30, 2024, due to stock-based compensation.
Current Maturities of Convertible Notes Payable: $1,208,235 — Increased from $1,078,235 on September 30, 2024, adding to short-term debt burden.
Micropearl Production Time: 8 days — The time it takes for the Hypha Micropearl accelerator to produce enriched mycelium.
Net Loss: $1,000 — for the three months ended March 31, 2025, an improvement from the prior year
Period End Date: 2025-03-31 — reporting period for the 10-Q
Fiscal Year End: 20240930 — The end date for the reporting period covered by the 10-K.
Filing Date: 20250113 — The date the 10-K was officially submitted to the SEC.
Prior Fiscal Year End: 2023-09-30 — The end date of the previous fiscal year, used for comparative financial analysis.

Frequently Asked Questions

What are the latest SEC filings for Hypha Labs, INC. (FUNI)?

Hypha Labs, INC. has 15 recent SEC filings from Jan 2024 to Aug 2025, including 6 10-Q, 6 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of FUNI filings?

Across 15 filings, the sentiment breakdown is: 2 bearish, 13 neutral. The dominant sentiment is neutral.

Where can I find Hypha Labs, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Hypha Labs, INC. (FUNI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Hypha Labs, INC.?

Key financial highlights from Hypha Labs, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for FUNI?

The investment thesis for FUNI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Hypha Labs, INC.?

Executive information for Hypha Labs, INC. is extracted from SEC filings as they are enriched with AI analysis.

What are the main risk factors for Hypha Labs, INC. stock?

Of FUNI's 15 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 6 low-risk.

What are recent predictions and forward guidance from Hypha Labs, INC.?

Forward guidance and predictions for Hypha Labs, INC. are extracted from SEC filings as they are enriched.